Kyverna Therapeutics/$KYTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kyverna Therapeutics
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
- Ticker
- $KYTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 129
- Headquarters
- EmeryVille, United States
- Website
- kyvernatx.com
KYTX Metrics
BasicAdvanced
$489m
-
-$2.88
-
-
Price and volume
Market cap
$489m
52-week high
$13.67
52-week low
$2.96
Average daily volume
992k
Financial strength
Current ratio
9.058
Quick ratio
8.746
Long term debt to equity
19.011
Total debt to equity
19.932
Interest coverage (TTM)
-88.69%
Profitability
EBITDA (TTM)
-157.364
Management effectiveness
Return on assets (TTM)
-44.51%
Return on equity (TTM)
-87.24%
Valuation
Price to book
2.99
Price to tangible book (TTM)
2.99
Price to free cash flow (TTM)
-2.662
Free cash flow yield (TTM)
-37.57%
Free cash flow per share (TTM)
-3.024
Growth
Earnings per share change (TTM)
-21.58%
What the Analysts think about KYTX
Analyst ratings (Buy, Hold, Sell) for Kyverna Therapeutics stock.
KYTX Financial Performance
Revenues and expenses
KYTX Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.